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The pain would be a challenging issue especially 
in acute patients with difficult experiences. Even 
though the direct correlation between activation 
and nociceptors and the sensory experience of pain 
is not always apparent, nevertheless emotional state, 
the degree of anxiety, attention and distraction, past 
experiences, memories, and other factors can either 
enhance or diminish the pain experience.
Recently, experts are getting interested in the 
supraspinal pathway. Supraspinal modulation is 
one path of pain pathway that would be happened 
during pain modulation. It is a specific system in 
pain pathway that blocks pain transmission in 
the central nervous system which consists of the 
periaqueductal gray (PAG), periventricular areas, 
raphe magnus nucleus (RMN), and pain inhibitory 
complex (PIC). Another important thing to be 
considered is that the pain process is an intertwined 
process that could not be cut abruptly. While we are 
elaborating and defining a pathway, it also contrib-
utes to other pathway and induces other things as 
well. This matter would be taken into concern when 
applied to pain management. 
CASE REPORT
A 41-year-old man admitted to hospital with a 
closed fracture of the right femur and he under-
went plate and screw fixation under anesthesia. 
A pre-anesthetic lookup summarized that he was 
obese (his body mass index was 30 kg/m2) with a 
history of behavioral opioid usage and sedatives. His 
pain score upon admission was reached 80/100 mm 
which was measured using a visual analog scale 
(VAS). He was dissatisfied with pain management 
efforts consisting of high dose morphine combined 
with pregabalin, NSAID, and paracetamol. Upon 
evaluation, he was able to spontaneously open 
his eyes, agitated, with markedly elevated pulses 
134-140 beats per minutes and respiratory rate 
14-16 per minutes. 
The surgery went unremarkable. For postsurgi-
cal pain management, the epidural analgesia was 
given with bupivacaine 0.1% and 2 mg of morphine 
as an adjuvant. The VAS score slightly decreased to 
70/100 mm. But still, he was not satisfied. We finally 
gave him the combination of bupivacaine 0.1% 
with 2 mg of morphine and 30 mcg of clonidine in 
10 ml solution every 12 hours. VAS was markedly 
decreased to 20/100. Hemodynamic curves were in 
normal limits, no complaints of paralysis, urinary 
difficulties, post-operative nausea and vomiting 
(PONV), or pruritus. He was discharged on the 
fourth day postsurgical with crutches.
Conventional workup showed that the patient 
was amphetamine and heroin user, complicated 
with an anxiety disorder. Complete pain resolution 
was seen in seven days postsurgery without any 
additional intravenous opioid or even antianxiety 
medications.
Department of Anesthesiology, 
Pain Medicine, and Intensive Care 
Faculty of Medicine Udayana 
University Sanglah General 
Hospital, Denpasar – Bali, 
Indonesia
*Correspondence to:   
I Made Gede Widyana, Department 
of Anesthesiology, Pain Medicine, 
and Intensive Care Faculty of 
Medicine, Udayana University Jl. 










Acute pain patients with complicated pain-related experiences would 
need more than just a pain reliever, especially those with behavioral 
opioid usage. Latest findings revolving supraspinal modulation are 
not only taking experts and pain physician into a different stage of 
understanding but also making theories and management revisited. 
A 41-years-old Australian male underwent plate and screw fixation of 
his right femur. He was overweight with a history of behavioral opioid 
usage. He was given epidural analgesia for postsurgical management 
with bupivacaine 0.1% with morphine 2 mg and clonidine 30 mcg 
every 12 hours as adjuvants. Hemodynamic curves were in normal 
limits, no paralysis, urinary difficulties, or pruritus. He was discharged 
on the fourth day. The combined morphine-clonidine adjuvant in 
epidural analgesia technique was an effective choice to alleviate pain 
response in this opioid-tolerant patient. 
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DISCUSSION
Pain is a vital function in providing our body with 
a warning of potential or actual injury. It is both 
sensory and emotional experiences and strongly 
affected by psychological factors such as past expe-
riences, belief, fear or anxiety. A patient who had 
been exposed with previous pain experiences and 
anxiety would need much more than just a pain 
reliever through opioid acts. The inherent pain 
memory had already perceived and rooted in the 
perception stage, and as we had reviewed, would be 
complicated with anxiety and fears. Their history of 
opioid usage and antianxiety medications would be 
taken into consideration when elaborating an effec-
tive and adequate pain regiment.1,2
Supraspinal modulation is a complex pathway 
that happens during pain modulation. It is a specific 
system in pain pathway that blocks pain transmis-
sion in the central nervous system which consists 
of the periaqueductal gray (PAG), periventricular 
areas, raphe magnus nucleus (RMN), and pain 
inhibitory complex (PIC).1 The periaqueductal gray 
and periventricular areas of the mesencephalon and 
upper pons surround the aqueduct of Sylvius (peri-
aqueductal) and portions of the third and fourth 
ventricles (periventricular). On the other hand, the 
RMN is a thin midline nucleus located in the lower 
pons and upper medulla, and the nucleus reticu-
laris paragigantocellularis, located laterally in the 
medulla. Pain inhibitory complex is located in the 
dorsal horn of the spinal cord consists of multiple 
short enkephalinergic neurons that terminate on 
central endings of pain conducting afferent fibers.1
The analgesia occurs as in the thalamus, hypo-
thalamus and cerebral cortex send neuronal signals 
to the periaqueductal grey area. The PAG projects 
neurons containing aspartate and glutamate that 
stimulate RMN. Then RMN projects serotonergic 
neurons, in addition to noradrenergic neurons 
projected from adjacent medulla to dorsal horn. 
They will block pain signals by activating PIC. 
When this complex is stimulated, encephalin would 
be released, and caused pre and postsynaptic inhi-
bition of pain transmission.1
Supraspinal modulation process is also related 
to opioid receptor modulation. The opioid peptides 
are morphine-like substances that act by binding to 
opiate receptors in the analgesic system and dorsal 
horn of the spinal cord on the central ending of 
pain conducting pain fibers. The opioid peptides 
consist of endorphin, encephalin, dynorphin, and 
endogenous morphine. Neurons using endorphin 
or encephalin are found in PAG where they inhibit 
GABA-anergic interneurons that normally suppress 
the anti-nociceptor neurons. Encephalin is used by 
interneurons in lamina II responsible for inhibiting 
the lamina-I nociceptor-specific spinothalamic 
neurons.1,3 Dynorphin could be found in the hypo-
thalamus, PAG, reticular formation, and dorsal 
horn, while endogenous morphine is in terminals 
forming synapses with neuron having µ-opioid 
receptors in pain modulation.2 
A failure in supraspinal modulation would 
contribute to central sensitization. Central sensi-
tization occurs when pain pathways in the spinal 
cord become hyperexcitable and are augmented, 
rather than blocked, in the thalamus and other 
brain centers. This leads to a cascade of neuroin-
flammatory, neuroendocrine, and autonomic 
dysregulation.1,3 
The concept of supraspinal modulation which 
consists of a descending pain modulatory system 
provides many targets for the development of anal-
gesic drugs or adjuncts that enhance the effects 
of existing analgesics. Opioids act throughout the 
neuraxis and can relieve pain through activities at 
cortical and subcortical sites, at which affective and 
somatosensory aspects of the pain experience can 
be modified, as well as by activating descending 
pain inhibitory circuits. As seen on our patient, the 
addition of morphine as an adjuvant could acti-
vate the descending pain inhibitory circuits which 
in turn would help the local anesthetic work in 
neuraxial scope.1 
Meanwhile, activation of descending norad-
renergic projections from the locus coeruleus and 
other noradrenergic sites produces antinociception. 
Accordingly, α2-adrenergic receptor agonists have 
been shown to produce antinociception as well as to 
potentiate the antinociceptive effect of opioid. Our 
patient was given combined adjuvant morphine with 
α2-adrenergic receptor agonist clonidine to potenti-
ate morphine effect and suppress the locus coeruleus. 
Locus coeruleus pontine is the most abundant place 
of alpha-2 receptors, an important source of sympa-
thetic innervation of the forebrain, and a vital alert 
center. The effects of sedation are due to inhibition 
of coeruleus nucleus.2 Clonidine is able to provide 
analgesia effects both peripherally, spinally, and 
supraspinal. The mechanism of clonidine analgesia 
at spinal level is, among others, through constraints 
of excitation on primary afferent nerves at the central 
terminal, resistance to release of substance-P and 
hyperpolarization, and a decrease in spontaneous 
activity of dorsal horn nerve.2 On the other hand, 
supraspinal level analgesia is reached through resis-
tance to afferent nerve substantia gelatinosa and 
some nuclei in the brainstem. Peripheral level anal-
gesia is also achieved by weakening the excitation 
of A-delta and C fibers and blocking conduction 
through increasing potassium conductance.5
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Clonidine at supraspinal level affects the nucleus 
in the brain stem activating alpha-2-postsynaptic 
adrenoreceptor and nonadrenergic imidazole bonds 
in lateral reticular nucleus resulting in a reduction of 
sympathetic tone. Clonidine at the peripheral level 
also act on adrenoceptor alpha-2-presynaptic and 
reduces the release of norepinephrine in sympa-
thetic nerve terminals thereby causing dilatation of 
blood vessels and reducing the chronotropic effect 
on the heart.18 But those negative effects on hemo-
dynamics were not found in our patient.5 
These modulatory pathways help to explain how 
personal experience and emotional state, as well as 
societal beliefs, may alter the experience of pain in 
which happened in patients with previous discom-
fort experiences.5
In this case report, we used the clonidine the 
co-administration of clonidine reducesthe dose of 
bupivacaine and improves the quality of spinal anes-
thesia. The antinociceptive properties of clonidine 
indicate that it might be useful as an alternative to 
intrathecal opioids for postoperative analgesia, thus 
avoiding the main adverseeffects, such as respira-
tory depression, pruritus, and urinary retention. 
The intrathecal application of clonidine increases 
the duration of both sensory and motor block2-5 
as well as postoperative analgesia. The mechanism 
of clonidine in spinal anesthesia is reported to be 
mediated by presynaptic (inhibition of transmitter 
release) and postsynaptic (enhancing hyperpolar-
ization) effects.6
CONCLUSION
Supraspinal modulation has been theoretically 
explained many years ago. It was totally not only a 
theory but could be perceived into cases and real 
practices, in which one of our patients had come 
into. By combining morphine and clonidine as 
adjuvants for local anesthetic in the epidural regi-
ment, the opioid and α2-adrenergic receptor agonist 
worked synergistically as antinociceptive agents 
and potentiated neuraxial blockade. Somatosensory 
and opioid receptor modulation were affected by 
morphine, while sympathetic innervation and 
activation were blocked by clonidine. Combined 
adjuvant agents would be beneficial in compli-
cated patients who would not be satiated with only 
opioids. 
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